Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1997-11-06
1999-11-02
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
4242041, 4242081, 4242341, 4242771, 530350, A61K 3938, A61K 3921, A61K 3902, A61K 3900
Patent
active
059765399
ABSTRACT:
Improved vaccine compositions and methods of making same are provided, which vaccines are characterized by an antigen from a pathogen and an effective adjuvanting amount of Interleukin-12. These IL-12 adjuvanted vaccines are capable of increasing the vaccinated host's cell mediated immune response to provide an increased and protective immune response to the pathogen. Also disclosed are methods for vaccinating hosts by administering a vaccine containing an antigen from a pathogenic microorganism and co-administering an adjuvanting amount of IL-12. Vaccines or therapeutic compositions directed against a cancer may also be adjuvanted with IL-12 according to this invention.
REFERENCES:
patent: 5457038 (1995-10-01), Trinchieri et al.
T. Mosmann et al, "Two Types of Murine Helper T Cell Clone", J. Immunol., 136(7):2348-2357 (Apr. 1, 1986).
H. Warren et al, "Current Status of Immunological Adjuvants", Ann. Rev. Immunol., 4:369-388 (Apr., 1986).
A. D'Andrea et al, "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells", J. Exp. Med., 176:1387-1398 (Nov., 1992).
M. Kobayashi et al, "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes", J. Exp. Med., 170:827-845 (Sep., 1989).
S. Chan et al, "Induction of Interferon .gamma. Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers", J. Exp. Med., 173:869-879 (Apr., 1991).
F. Heinzel et al, "Recombinant Interleukin 12 Cures Mice Infected with Leishmania Major", J. Exp. Med., 177:1505-1509 (May, 1993).
J. Sypek et al, "Resolution of Cutaneous Leishmaniasis: Interleukin 12 Initiates a Protective T Helper Type 1 Immune Response", J. Exp. Med., 177:1797-1802 (Jun., 1993).
A. McKnight et al, "Effectsof IL-12 on Helper T Cell-Dependent Immune Responses in vivo", J. Immunol., 152:2172-2179 (Jun., 1994).
L. Afonso et al, "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major", Science, 263:235-237 (Jan. 14, 1994).
C-S. Hsieh et al, "Development of T.sub.H 1 CD4.sup.+ T Cells Through IL-12 Produced by Listeria-Induced Macrophages", Science, 260:547-549 (Apr. 23, 1993).
P. Scott, "IL-12: Initiation Cytokine for Cell-Mediated Immunity", Science, 260:496-497 (Apr. 23, 1993).
R. Manetti et al, "Natural Killer Cell Stimulatory Factor (Interleukin 12 [IL-12]) Induces T Helper Type 1 (Th1)-Specific Immune Responses and Inhibits the Development of IL-4-Producing Th Cells", J. Exp. Med., 177:1199-1204 (Apr., 1993).
G. Freeman et al, "B7, a New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells", J. Immunol., 143(8):2714-2722 (Oct. 15, 1989).
K. Jerome et al, "Tumor-Specific Cytotoxic T Cell Clones from Patients with Breast and Pancreatic Adenocarcinoma Recognize EBV-Immortalized B Cells Transfected with Polymorphic Epithelial Mucin Complementary DNA", J. Immunol., 151(3):1654-1662 (Aug. 1, 1993).
R. Kurth et al, "The Quest for an AIDS Vaccine: The State of the Art and Current Challenges", AIDS Research and Human Retroviruses, 7(5):425-433 (1991).
G. Butcher, "Mechanisms of Immunity to Malaria and the Possibilities of a Blood-Stage Vaccine: A Critical Appraisal", Parasitology, 98:315-327 (1989).
W. Greene, "AIDS and the Immune System, the AIDS Virus Exploits the Immune System to Replicate Itself. New Findings are Showing how it Wreaks Havoc on the Body's Defenses", Scientific American, pp. 99-105 (Sep., 1993).
D. Hentges, "Medical Microbiology, A Review with Questions and Explanations", pp. 14-18, 25-29, 206-209, 286-287 (1986).
T. Wynn et al, "Endogenous Interleukin 12 (IL-12) Regulates Granuloma Formation Induced by Eggs of Schistosoma mansoni and Exogenous IL-12 Both Inhibits and Prophylactically Immunizes Against Egg Pathology", J. Exp. Med., 179:1551-1561 (May, 1994) [Wynn I].
T. Wynn et al, "An IL-12-based Vaccination Method for Preventing Fibrosis Induced by Schistosome Infection", Nature, 376:594-596 (Aug. 17, 1995) [Wynn II].
T. Wynn et al, "IL-12 Enhances Vaccine-Induced Immunity to Schistosoma mansoni in Mice and Decreases T Helper 2 Cytokine Expression, IgE Production, and Tissue Eosinophilia", J. Immunol., 154:4701-4709 (1995) [Wynn III].
T. Wynn et al, "IL12 an an Adjuvant for Vaccines Designed to Prevent Infection and Immunopathology by Schistosomes", Res. Immunol., 146:582-590 (1995) [Wynn IV].
T. Germann et al, "The Influence of IL12 on the Development of Th1 and Th2 Cells and its Adjuvant Effect for Humoral Immune Respones", Res. Immunol., 146:481-485 (1995).
M. Miller et al, "Nonviable Bacterial Antigens Administered with IL-12 Generate Antigen-Specific T Cell Responses and Protective Immunity Against Listeria monocytogenes", J. Immunol., 155:4817-4828 (1995).
Y. Noguchi et al, "Influence of Interleukin 12 on p53 Peptide Vaccination Against Established Meth A Sarcoma", Proc. Natl. Acad. Sci. USA, 92:2219-2223 (Mar., 1995).
Y-W. Tang et al, "Interleukin-12 Treatment During Immunization Elicits a T Helper Cell type 1-like Immune Response in Mice Challenged with Respiratory Syncytial Virus and Improves Vaccine Immunogenicity", J. Infect. Dis., 172:734-738 (Sep., 1995).
S. Wolf et al, "Activity of IL12 as Adjuvant in Promoting Th1 and Th2 Recall Responses", Res. Immunol., 146:486-493 (1995).
J. Bliss et al, "IL-12, as an Adjuvant, Promotes a T Helper 1 Cell, but does not Suppress a T Helper 2 Cell Recall Response", J. Immunol., 156:887-894 (1996).
J. Rao et al, "IL-12 is an Effective Adjuvant to Recombinant Vaccinia Virus-Based Tumor Vaccines", J. Immunol., 156:3357-3365 (1996).
M. Vagliani et al, "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells", Cancer Research, 56:467-470 (Feb. 1, 1996).
M. Rodolfo et al, "Immunotherapy of Experimental Metastases by Vaccination with Interleukin Gene-Transduced Adenocarcinoma Cells Sharing Tumor-Associated Antigens", J. Immunol., 157:5536-5542 (1996).
T. Germann et al, "Interleukin-12 Profoundly Up-Regulates the Synthesis of Antigen-Specific Complement-Fixing IgG2a, IgG2b and IgG3 Antibody Subclasses in vivo", Eur. J. Immunol., 25:823-829 (1995).
S. Hall, "IL-12 at the Crossroads", Science, 268:1432-1434 (Jun. 9, 1995).
A. Nohria et al, "Cytokines as Potential Vaccine Adjuvants", Biotherapy, 7:261-269 (Oct. 18, 1994).
S. Townsend et al, "Tumor Rejection After Direct Costimulation of CD8.sup.+ T Cells by B7-Transfected Melanoma Cells", Science, 259:368-370 (Jan. 15, 1993).
E. Mougneau et al, "Expression Cloning of a Protective Leishmania Antigen", Science, 268:563-566 (Apr. 28, 1995).
J. Hadden, "Review Article--T-Cell Adjuvants", Int. J. Immunopharmac., 16(9):703-710 (Aug. 31, 1994).
German Patent Application No. DE 3922444, published Jan. 10, 1991 (Abstract only).
K. Irvine et al, "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases", J. Immunol., 156:238-245 (1996).
C. Coughlin et al, "B7-1 and Interleukin 12 Synergistically Induce Effective Antitumor Immunity", Cancer Research, 55:4980-4987 (Nov. 1, 1995).
H. Kurzawa et al, "Recombinant Interleukin 12 Enhances Cellular Immune Responses to Vaccination Only After a Period of Suppression", Cancer Research, 58:491-499 (Feb. 1, 1998).
Afonso, et al, "The Adjuvant Effect of IL-12 in a Vaccine . . . " Science 26: 235-237, 1994.
Scott Phillip
Trinchieri Giorgio
Eisenschenk Frank C.
Nelson Bremy
The Trustees of the University of Pennsylvania
The Wistar Institute of Anatomy and Biology
LandOfFree
Compositions and methods for use of IL-12 as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for use of IL-12 as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for use of IL-12 as an adjuvant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2131475